Replies to post #2729 on Enanta Pharmaceuticals Inc (ENTA)

[alertmeipp]

PFE expects Paxlovid 2023 sales to be around 8b, So I would think 325 is viable and worth more than zero. But the concern seems to be its regulatory pathway?

From RBC: "the U.S. regulatory path currently emphasizes demonstration of outcomes benefits (hospitalization, mortality, etc.) and this would be difficult to show in the current environment, barring a major mutation."

[biotech_researcher]

Dew, I recall a robust pipeline at Enanta BEFORE Covid. What happened to those programs? Seems like there were 3 or 4…